...it plans to partner the product and expects to launch it in 1H12. In 2009, Biotec Pharmacon...
...SBG inactive in Phase III trials (see BioCentury, Dec. 7, 2009 & Oct. 4, 2010). Biotec Pharmacon...

...were used in Phase III testing non-significantly improved wound healing vs. vehicle controls. In February, Biotec Pharmacon...
...target ulcers healed at week 8 vs. SOC plus placebo (see BioCentury, Dec. 7, 2009). Biotec Pharmacon...

...studies with SBG in a number of product containers to confirm the hypothesis. In November, Biotec Pharmacon...
...BioCentury, Dec. 7, 2009). SBG is also in Phase III testing for oral mucositis (OM). Biotec Pharmacon...

...$3.8 million) for the nine months ended Sept. 30, 2009. Creo Advisors A/S advised Biotec Pharmacon. Biotec Pharmacon...
...said the move allows it to focus on its core pharmaceuticals and marine chemicals businesses. Biotec Pharmacon...
...soluble beta-1,3/1,6-glucan is also in Phase III testing for oral mucositis. At Sept. 30, 2009, Biotec Pharmacon...

...benign and malignant pelvic masses; cash includes $43.1M raised in a December private placement 12/11/09 Biotec Pharmacon...

...patients who no longer respond to a DMARD, citing risk of progressive multifocal leukoencephalopathy (PML) Biotec Pharmacon...